Kılıçlı, Fatih Cumhuriyet Üniversitesi - Tıp Fakültesi - Endokrinoloji ve Metabolizma, Turkey , Dökmetaş, Hatice Sebila Cumhuriyet University - Faculty of Medicine - Department of Endocrinology and Metabolism, Turkey , Keleştimur, Fahrettin Erciyes University - Faculty of Medicine - Department of Endocrinology and Metabolism, Turkey , Korkmaz, Serdal Gemerek State Hospital - Internal Medicine Clinic, Turkey

A successful pregnancy in a patient with acromegaly under octreotide-LAR treatment: a case report

32960

The patient was a 30 -year-old female acromegaly patient who was operated for pituitary macroadenoma. The response to postoperative oral glucose tolerance test (OGTT) after operation was insufficient. For this reason, Octreotide-LAR (OCT-LAR) treatment was started. On 15 months after the therapy, the patient presented with failure of menstruation for four months, so pregnancy test was performed and pregnancy was diagnosed. The patient had used OCT-LAR during the period without knowing that she was pregnant. Since it has been shown with magnetic resonance imaging (MRI) that the pituitary adenoma did not grow, we stopped the OCT-LAR treatment. The patient delivered a healthy newborn girl of 2650 g in weight and 50 cm in length at the 37 weeks of gestation. MRI was performed for postpartum macroadenoma assessment and the lesion did not grow during this period. Two months after the delivery, the response of growth hormone to OGTT was evaluated. OCT LAR treatment was started again because the suppression was not seen. We believe that the size of the adenoma must be checked by MRI to make a decision in discontinuing or continuing treatment as the most suitable approach, when pregnancy develops in acromegalic patients. Furthermore, we think that OCT-LAR should be discontinued during pregnancy until more safety data are obtained.

226

Acromegaly , pregnancy , octreotide

Cumhuriyet Medical Journal

229